Contribute Try STAT+ Today

So-called undruggable proteins — those that supposedly can’t be targeted by pharmaceuticals — represent a big barrier in discovering new drugs for complex diseases like cancer, autoimmune disorders, and others that continue to be major causes of disability and death. As someone who has spent decades in academic research and more recently in the biotech industry, I’m betting that the biopharmaceutical research community will overcome this problem to treat, and potentially cure, these and other diseases.

Why? In part because the dominant model that has ruled drug discovery for decades is starting to give way to a new approach that harnesses the power of biology to tackle previously undruggable disease targets. This shift represents a staggering potential for advancement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.